Analysed HUTCHMED CHINA-ADR (HCM:NASDAQ) News Sources
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
23-04-2026
yahoo.com
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
29-04-2026
marketbeat.com
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
29-04-2026
yahoo.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
29-04-2026
yahoo.com
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21-05-2026
yahoo.com
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21-05-2026
yahoo.com
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
02-06-2026
yahoo.com
What is the current price of HUTCHMED CHINA-ADR (HCM:NASDAQ)?
The current price of HUTCHMED CHINA-ADR (HCM:NASDAQ) is $10.96.
HUTCHMED CHINA-ADR (HCM:NASDAQ) absolute price change since previous trading day?
The absolute price change of HUTCHMED CHINA-ADR (HCM:NASDAQ) since the previous trading day is $0.28.
HUTCHMED CHINA-ADR (HCM:NASDAQ) percentage price change since previous trading day?
The percentage price change of HUTCHMED CHINA-ADR (HCM:NASDAQ) since the previous trading day is 2.6217%.
What is the most recent average sentiment score for HUTCHMED CHINA-ADR (HCM:NASDAQ)?
The most recent average sentiment score for HUTCHMED CHINA-ADR (HCM:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for HUTCHMED CHINA-ADR (HCM:NASDAQ)?
The most recent sentiment for HUTCHMED CHINA-ADR (HCM:NASDAQ) is .
SEC-8K** Filing Available For HUTCHMED CHINA-ADR (HCM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.